omega-3 fatty acids (Hospital San Juan de la Cruz)

Omega-3 fatty acids are being investigated in the Phase 3 PROTEICA trial (Polyunsaturated Omega-3 Fatty Acids on Serum Albumin Concentration in Patients with Acute Heart Failure, Hypoalbuminemia and Elevated Inflammatory Activity) conducted by Hospital San Juan de la Cruz in Spain. This specific investigational use focuses on patients with acute heart failure (AHF) who also present with hypoalbuminemia (serum albumin ≤ 3.4 g/dL) and elevated inflammatory activity (C-reactive protein ≥ 25 mg/L). The treatment involves a high-dose oral regimen of 4 grams daily of omega-3 polyunsaturated fatty acids (PUFAs). The therapeutic rationale is that omega-3 PUFAs can modulate systemic inflammation, thereby correcting hypoalbuminemia, which is a significant prognostic factor in acute heart failure. The trial evaluates changes in serum albumin and CRP levels over a 4-week period.

Other names

omega-3 polyunsaturated fatty acidsomega3 polyunsaturated fatty acidsomega 3 polyunsaturated fatty acidsomega-3 PUFAsomega3 PUFAsomega 3 PUFAsn-3 PUFAsn3 PUFAsn 3 PUFAsomega-3-acid ethyl estersomega3-acid ethyl estersomega 3-acid ethyl esters